Abstract | PURPOSE: MATERIALS AND METHODS: RESULTS: CONCLUSIONS: Following maximum androgen blockade with an alternative nonsteroidal antiandrogen is effective for advanced prostate cancer that has relapsed after initial maximum androgen blockade. Even a partial response to second line maximum androgen blockade was associated with improved survival. Our data support the notion that responders to second line regimens are androgen independent but still hormonally sensitive.
|
Authors | Hiroyoshi Suzuki, Koji Okihara, Hideaki Miyake, Masato Fujisawa, Susumu Miyoshi, Tetsuro Matsumoto, Motohiro Fujii, Yoshio Takihana, Tsuguru Usui, Tadashi Matsuda, Seiichiro Ozono, Hiromi Kumon, Tomohiko Ichikawa, Tsuneharu Miki, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group |
Journal | The Journal of urology
(J Urol)
Vol. 180
Issue 3
Pg. 921-7
(Sep 2008)
ISSN: 1527-3792 [Electronic] United States |
PMID | 18635218
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Androgen Antagonists
- Anilides
- Antineoplastic Agents, Hormonal
- Nitriles
- Tosyl Compounds
- Flutamide
- bicalutamide
- Prostate-Specific Antigen
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Androgen Antagonists
(therapeutic use)
- Anilides
(therapeutic use)
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Flutamide
(therapeutic use)
- Humans
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Nitriles
(therapeutic use)
- Prostate-Specific Antigen
(blood)
- Prostatic Neoplasms
(drug therapy)
- Substance Withdrawal Syndrome
- Survival Analysis
- Tosyl Compounds
(therapeutic use)
- Treatment Outcome
|